Overdiagnosis and overtreatment of prostate cancer.

[1]  A. Dicker,et al.  Patterns of Care for Elderly Men Diagnosed With Favorable-risk Prostate Cancer From 2004 to 2008: A Population-based Analysis , 2013, American journal of clinical oncology.

[2]  P. Stattin,et al.  Population based study of use and determinants of active surveillance and watchful waiting for low and intermediate risk prostate cancer. , 2013, The Journal of urology.

[3]  B. G. Blijenberg,et al.  Screening for prostate cancer: results of the Rotterdam section of the European randomized study of screening for prostate cancer. , 2013, European urology.

[4]  T. H. van der Kwast,et al.  Prevalence of prostate cancer on autopsy: cross-sectional study on unscreened Caucasian and Asian men. , 2013, Journal of the National Cancer Institute.

[5]  Ruth Etzioni,et al.  Influence of Study Features and Methods on Overdiagnosis Estimates in Breast and Prostate Cancer Screening , 2013, Annals of Internal Medicine.

[6]  A. Costello,et al.  Patterns of care for men diagnosed with prostate cancer in Victoria from 2008 to 2011 , 2013, The Medical journal of Australia.

[7]  T. Tammela,et al.  Prostate cancer mortality in the Finnish randomized screening trial. , 2013, Journal of the National Cancer Institute.

[8]  H. D. de Koning,et al.  Treatment of local–regional prostate cancer detected by PSA screening: benefits and harms according to prognostic factors , 2013, British Journal of Cancer.

[9]  John W. Davis,et al.  Retracted: Many young men with prostate‐specific antigen (PSA) screen‐detected prostate cancers may be candidates for active surveillance , 2013, BJU international.

[10]  M. Cooperberg,et al.  2131 DEVELOPMENT AND VALIDATION OF THE BIOPSY-BASED GENOMIC PROSTATE SCORE (GPS) AS A PREDICTOR OF HIGH GRADE OR EXTRACAPSULAR PROSTATE CANCER TO IMPROVE PATIENT SELECTION FOR ACTIVE SURVEILLANCE , 2013 .

[11]  B. Jeong,et al.  Detection rate of clinically insignificant prostate cancer increases with repeat prostate biopsies. , 2013, Asian journal of andrology.

[12]  Ruth Etzioni,et al.  Comparative Effectiveness of Alternative Prostate-Specific Antigen–Based Prostate Cancer Screening Strategies , 2013, Annals of Internal Medicine.

[13]  G. Draisma,et al.  A note on the catch-up time method for estimating lead or sojourn time in prostate cancer screening , 2013, Statistics in medicine.

[14]  P. Boyle,et al.  Critical role of prostate biopsy mortality in the number of years of life gained and lost within a prostate cancer screening programme , 2012, BJU international.

[15]  M. Cooperberg,et al.  Prostate Cancer Mortality following Active Surveillance versus Immediate Radical Prostatectomy , 2012, Clinical Cancer Research.

[16]  J. Groopman,et al.  There is more to life than death. , 2012, The New England journal of medicine.

[17]  S. Duffy,et al.  Overdiagnosis in Mammographic Screening for Breast Cancer in Europe: A Literature Review , 2012, Journal of medical screening.

[18]  H. D. de Koning,et al.  Quality-of-life effects of prostate-specific antigen screening. , 2012, The New England journal of medicine.

[19]  S. Rosso,et al.  Changes in incidence, survival and mortality of prostate cancer in Europe and the United States in the PSA era: additional diagnoses and avoided deaths. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

[20]  B. G. Blijenberg,et al.  Prostate-cancer mortality at 11 years of follow-up. , 2012, The New England journal of medicine.

[21]  E. Metter,et al.  Prostate‐specific antigen velocity (PSAV) risk count improves the specificity of screening for clinically significant prostate cancer , 2012, BJU international.

[22]  W. Shih,et al.  The impact of PSA testing frequency on prostate cancer incidence and treatment in older men , 2011, Prostate Cancer and Prostatic Diseases.

[23]  Ruth Etzioni,et al.  Long-term projections of the harm-benefit trade-off in prostate cancer screening are more favorable than previous short-term estimates. , 2011, Journal of clinical epidemiology.

[24]  H. D. de Koning,et al.  Interpreting Overdiagnosis Estimates in Population-based Mammography Screening , 2011, Epidemiologic reviews.

[25]  H. Ahmed,et al.  Multi-Parametric Magnetic Resonance Imaging to Rule-In and Rule-Out Clinically Important Prostate Cancer in Men at Risk: A Cohort Study , 2011, Urologia Internationalis.

[26]  S. Greenfield,et al.  Overtreatment of men with low‐risk prostate cancer and significant comorbidity , 2011, Cancer.

[27]  E. Metter,et al.  What is the true number needed to screen and treat to save a life with prostate-specific antigen testing? , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  A. D'Amico,et al.  Comorbidity and mortality results from a randomized prostate cancer screening trial. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  H. D. de Koning,et al.  Lead-time in the European Randomised Study of Screening for Prostate Cancer. , 2010, European journal of cancer.

[30]  T. Tammela,et al.  Results of the three rounds of the Finnish Prostate Cancer Screening Trial—The incidence of advanced cancer is decreased by screening , 2010, International journal of cancer.

[31]  P. Peele,et al.  Cost comparison between watchful waiting with active surveillance and active treatment of clinically localized prostate cancer. , 2010, Urology.

[32]  J. Hugosson,et al.  Mortality results from the Göteborg randomised population-based prostate-cancer screening trial. , 2010, The Lancet. Oncology.

[33]  R. DiPaola,et al.  Risk profiles and treatment patterns among men diagnosed as having prostate cancer and a prostate-specific antigen level below 4.0 ng/ml. , 2010, Archives of internal medicine.

[34]  H. Welch,et al.  Overdiagnosis in cancer. , 2010, Journal of the National Cancer Institute.

[35]  A. Vickers,et al.  Empirical Estimates of the Lead Time Distribution for Prostate Cancer Based on Two Independent Representative Cohorts of Men Not Subject to Prostate-Specific Antigen Screening , 2010, Cancer Epidemiology, Biomarkers & Prevention.

[36]  T. Guzzo,et al.  Repeat prostate biopsy and the incremental risk of clinically insignificant prostate cancer. , 2010, Urology.

[37]  B. G. Blijenberg,et al.  Screening and prostate-cancer mortality in a randomized European study. , 2009, The New England journal of medicine.

[38]  H. D. de Koning,et al.  Overdetection, overtreatment and costs in prostate-specific antigen screening for prostate cancer , 2009, British Journal of Cancer.

[39]  Peter C Albertsen,et al.  Prostate cancer diagnosis and treatment after the introduction of prostate-specific antigen screening: 1986-2005. , 2009, Journal of the National Cancer Institute.

[40]  P. Carroll,et al.  Sociodemographic predictors of prostate cancer risk category at diagnosis: unique patterns of significant and insignificant disease. , 2009, The Journal of urology.

[41]  E. Feuer,et al.  Lead time and overdiagnosis in prostate-specific antigen screening: importance of methods and context. , 2009, Journal of the National Cancer Institute.

[42]  S. Duffy,et al.  Mean sojourn time, overdiagnosis, and reduction in advanced stage prostate cancer due to screening with PSA: implications of sojourn time on screening , 2009, British Journal of Cancer.

[43]  G. Bartsch,et al.  Clinical and pathological features of screen vs non‐screen‐detected prostate cancers: is there a difference? , 2008, BJU international.

[44]  G. Bartsch,et al.  Over‐diagnosis and under‐diagnosis of screen‐ vs non‐screen‐detected prostate cancers with in men with prostate‐specific antigen levels of 2.0–10.0 ng/mL , 2008, BJU international.

[45]  David C. Miller,et al.  Prostate cancer severity among low income, uninsured men. , 2008, The Journal of urology.

[46]  Ruth Etzioni,et al.  Estimating Lead Time and Overdiagnosis Associated with PSA Screening from Prostate Cancer Incidence Trends , 2008, Biometrics.

[47]  A. Haese*,et al.  Critical assessment of tools to predict clinically insignificant prostate cancer at radical prostatectomy in contemporary men , 2008, Cancer.

[48]  L. Irwig,et al.  Effects of study methods and biases on estimates of invasive breast cancer overdetection with mammography screening: a systematic review. , 2007, The Lancet. Oncology.

[49]  Nicolas Barry Delongchamps,et al.  Needle biopsies on autopsy prostates: sensitivity of cancer detection based on true prevalence. , 2007, Journal of the National Cancer Institute.

[50]  T. H. van der Kwast,et al.  Cancer detection and cancer characteristics in the European Randomized Study of Screening for Prostate Cancer (ERSPC)--Section Rotterdam. A comparison of two rounds of screening. , 2007, European urology.

[51]  G. Bartsch,et al.  Under diagnosis and over diagnosis of prostate cancer in a screening population with serum PSA 2 to 10 ng/ml. , 2007, The Journal of urology.

[52]  William J Catalona,et al.  Under diagnosis and over diagnosis of prostate cancer. , 2007, The Journal of urology.

[53]  E. Feuer,et al.  Reconstructing PSA testing patterns between black and white men in the US from Medicare claims and the National Health Interview Survey , 2007, Cancer.

[54]  John T. Wei,et al.  Incidence of initial local therapy among men with lower-risk prostate cancer in the United States. , 2006, Journal of the National Cancer Institute.

[55]  B. Dezső,et al.  The prevalence of prostate carcinoma and its precursor in Hungary: an autopsy study. , 2005, European urology.

[56]  E. Gillanders,et al.  Genome‐wide screen for prostate cancer susceptibility genes in men with clinically significant disease , 2005, The Prostate.

[57]  Barnett S Kramer,et al.  Prostate biopsy following a positive screen in the prostate, lung, colorectal and ovarian cancer screening trial. , 2005, The Journal of urology.

[58]  M. Zelen,et al.  Overdiagnosis in early detection programs. , 2004, Biostatistics.

[59]  A. Cesinaro,et al.  Immediate radical prostatectomy in patients with atypical small acinar proliferation. Over treatment? , 2004, The Journal of urology.

[60]  M. Cooperberg,et al.  The changing face of low-risk prostate cancer: trends in clinical presentation and primary management. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[61]  Hartwig Huland,et al.  Counseling men with prostate cancer: a nomogram for predicting the presence of small, moderately differentiated, confined tumors. , 2003, The Journal of urology.

[62]  Harry J de Koning,et al.  Lead times and overdetection due to prostate-specific antigen screening: estimates from the European Randomized Study of Screening for Prostate Cancer. , 2003, Journal of the National Cancer Institute.

[63]  Manuel Sánchez-Chapado,et al.  Prevalence of prostate cancer and prostatic intraepithelial neoplasia in Caucasian Mediterranean males: An autopsy study , 2003, The Prostate.

[64]  T. Tammela,et al.  Lead-time in prostate cancer screening (Finland) , 2002, Cancer Causes & Control.

[65]  A. Haese*,et al.  Stage Migration in Clinically Localized Prostate Cancer , 2000, European Urology.

[66]  J A Hanley,et al.  Screening for prostate cancer: estimating the magnitude of overdetection. , 1998, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.

[67]  K. Stamatiou,et al.  Frequency of impalpable prostate adenocarcinoma and precancerous conditions in Greek male population: an autopsy study , 2006, Prostate Cancer and Prostatic Diseases.

[68]  D. Grignon,et al.  High grade prostatic intraepithelial neoplasia (HGPIN) and prostatic adenocarcinoma between the ages of 20-69: an autopsy study of 249 cases. , 1994, In vivo.